Xing F Y, Liu W H, Dong W, Zhang S L, Gu B W, Okazaki K, Naito H, Inoue T, Wu J T, Tamura S
Dept. of Internal Medicine, Liaoning Tumor Hospital, China.
Gan To Kagaku Ryoho. 1993 Feb;20(2):259-63.
Efficacy of an alternative combination chemotherapy with MMC, VCR, MTX, 5-FU, CDDP and ADM for adenocarcinoma of the lung is reported. Forty-one advanced cases (stage III: 9; IV: 32) were chosen for the chemotherapy. Two combination chemotherapies MMC + VCR + MTX + 5-FU + CDDP: MVMFP; MMC + VCR + MTX + 5-FU + ADM: MVMFA were repeated alternatively for 8 consecutive weeks with 2 interposed rest weeks, and this regimen was completed in 34 cases. All 41 cases were evaluable. Three and 26 cases achieved complete and partial responses, respectively. The response rate was 70.7%, and the median survival time was 13 months. The adverse effects of the chemotherapy observed were tolerable: alopecia (63.4%), gastrointestinal symptoms (14.5%), bone marrow toxicity (12.2%) and liver dysfunction (4.8%). These results indicate that our MVMFP/MVMFA alternative chemotherapy is quite effective for adenocarcinoma of the lung, comparable or superior to conventional chemotherapies.
报告了一种含丝裂霉素（MMC）、长春新碱（VCR）、甲氨蝶呤（MTX）、5-氟尿嘧啶（5-FU）、顺铂（CDDP）和多柔比星（ADM）的替代联合化疗方案对肺癌腺癌的疗效。选择了41例晚期病例（Ⅲ期：9例；Ⅳ期：32例）进行化疗。两种联合化疗方案，即MMC + VCR + MTX + 5-FU + CDDP（MVMFP）和MMC + VCR + MTX + 5-FU + ADM（MVMFA）交替重复进行，连续8周，中间间隔2周休息，该方案在34例患者中完成。所有41例患者均可评估。分别有3例和26例患者达到完全缓解和部分缓解。缓解率为70.7%，中位生存时间为13个月。观察到的化疗不良反应可耐受：脱发（63.4%）、胃肠道症状（14.5%）、骨髓毒性（12.2%）和肝功能障碍（4.8%）。这些结果表明，我们的MVMFP/MVMFA替代化疗方案对肺癌腺癌相当有效，与传统化疗相当或更优。
